Viyash Scientific Limited has announced the appointment of Mr. Amit Jain and Mr. Abhiroop Jayanthi as Non-Executive, Non-Independent Directors, effective April 22, 2026. Both appointees represent the Carlyle group and bring extensive private equity and industry expertise to the board. Additionally, the company has revised its Employee Stock Option Scheme (ESOP) 2026, reducing the total option pool to 1,30,98,000 stock options.
Strengthening Board Leadership
In a significant move to bolster its governance, Viyash Scientific Limited has inducted two new members to its Board of Directors. Mr. Amit Jain, a Partner and Head of Carlyle India Advisors, brings deep expertise in buyout and control investments across technology and industrial sectors. Similarly, Mr. Abhiroop Jayanthi, a Managing Director at Carlyle, joins the board with over 15 years of experience in private equity, particularly in the healthcare and life sciences fields.
Both directors have been appointed as Non-Executive, Non-Independent members and are subject to retirement by rotation, pending approval from the company’s shareholders.
Revision of Employee Stock Option Scheme
Beyond board changes, the company has updated the financial framework for its talent incentive program. The board approved a revision to the ESOP 2026 pool. The total number of options available for grant has been adjusted to 1,30,98,000, reflecting a downward revision from the previously proposed 1,34,75,000 options.
Strategic Background
The new board members bring extensive professional credentials. Mr. Amit Jain holds an MBA from the Indian School of Business and a B.Tech from IIT Kharagpur, with past leadership roles at Blackstone and McKinsey. Mr. Abhiroop Jayanthi is a Wharton Business School MBA graduate and a former Managing Director at Bain Capital, recognized for his contributions to the Indian corporate landscape.
Source: BSE
